140 related articles for article (PubMed ID: 23692343)
1. Activity of dexrazoxane and amifostine against late cardiotoxicity induced by the combination of doxorubicin and cyclophosphamide in vivo.
Bjelogrlic SK; Lukic ST; Djuricic SM
Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):228-38. PubMed ID: 23692343
[TBL] [Abstract][Full Text] [Related]
2. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
[TBL] [Abstract][Full Text] [Related]
5. Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
Smith TA; Phyu SM; Akabuogu EU
Anticancer Res; 2016 Jan; 36(1):87-93. PubMed ID: 26722031
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of saponins from Panax notoginseng against doxorubicin-induced cardiotoxicity in mice.
Liu L; Shi R; Shi Q; Cheng Y; Huo Y
Planta Med; 2008 Feb; 74(3):203-9. PubMed ID: 18260050
[TBL] [Abstract][Full Text] [Related]
8. Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice.
Bjelogrlic SK; Radic J; Jovic V; Radulovic S
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):311-9. PubMed ID: 16236144
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
10. Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
Mladosievicova B; Foltinová A; Petrásová H; Bernadic M; Hulín I
Neoplasma; 2001; 48(1):61-5. PubMed ID: 11327539
[TBL] [Abstract][Full Text] [Related]
11. Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study.
QuanJun Y; GenJin Y; LiLi W; YongLong H; Yan H; Jie L; JinLu H; Jin L; Run G; Cheng G
PLoS One; 2017; 12(1):e0169567. PubMed ID: 28072830
[TBL] [Abstract][Full Text] [Related]
12. Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice.
Vijay V; Moland CL; Han T; Fuscoe JC; Lee T; Herman EH; Jenkins GR; Lewis SM; Cummings CA; Gao Y; Cao Z; Yu LR; Desai VG
Toxicol Appl Pharmacol; 2016 Mar; 295():68-84. PubMed ID: 26873546
[TBL] [Abstract][Full Text] [Related]
13. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.
Jahnukainen K; Jahnukainen T; Salmi TT; Svechnikov K; Eksborg S; Söder O
Cancer Res; 2001 Sep; 61(17):6423-7. PubMed ID: 11522636
[TBL] [Abstract][Full Text] [Related]
14. Radiopharmaceutical model using 99mTc-MIBI to evaluate amifostine protection against doxorubicin cardiotoxicity in rats.
Yurekli Y; Unak P; Ertay T; Biber Z; Medine I; Teksoz S
Ann Nucl Med; 2005 May; 19(3):197-200. PubMed ID: 15981672
[TBL] [Abstract][Full Text] [Related]
15. Desacyl ghrelin prevents doxorubicin-induced myocardial fibrosis and apoptosis via the GHSR-independent pathway.
Pei XM; Yung BY; Yip SP; Ying M; Benzie IF; Siu PM
Am J Physiol Endocrinol Metab; 2014 Feb; 306(3):E311-23. PubMed ID: 24326424
[TBL] [Abstract][Full Text] [Related]
16. [Prevention against and treatment of doxorubicin-induced acute cardiotoxicity by dexrazoxane and schisandrin B].
Hu KY; Yang Y; He LH; Wang DW; Jia ZR; Li SR; Tian W; Mao J; Li XJ; Zhang W
Yao Xue Xue Bao; 2014 Jul; 49(7):1007-12. PubMed ID: 25233631
[TBL] [Abstract][Full Text] [Related]
17. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
[TBL] [Abstract][Full Text] [Related]
20. Investigation of doxorubicin tissue toxicity: does amifostine provide chemoprotection? An experimental study.
Rigatos SK; Stathopoulos GP; Dontas I; Perrea-Kotsarelis D; Couris E; Karayannacos PE; Deliconstantinos G
Anticancer Res; 2002; 22(1A):129-34. PubMed ID: 12017274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
